Webcast Alert: Lippert/Heilshorn Life Sciences Conference Presentation (Achillion Pharmaceuticals, Inc.)

Business Wire, March 23, 2009

NEW YORK -- Achillion Pharmaceuticals, Inc. (ACHN) announces the following Webcast:

What: Lippert/Heilshorn Life Sciences Conference Presentation

When: March 26, 2009 @ 1:30 PM Eastern

Where: http://www.investorcalendar.com/ClientPage.asp?ID=142727

How: Live over the Internet -- Simply log on to the web at the address above.

Contact: Cheryl Palazzo, 212-838-3777, cpalazzo@lhai.com

If you are unable to participate during the live webcast, the call will be available for replay at http://www.investorcalendar.com/ClientPage.asp?ID=142727 or http://www.investorcalendar.com/

Achillion is an innovative biopharmaceutical company dedicated to bringing important new treatments to patients with infectious disease. The Company's highly skilled and experienced discovery and development teams have advanced multiple product candidates with novel mechanisms of action. Achillion is focused on solutions for the most challenging problems in infectious disease - HCV, resistant bacterial infections, and HIV.

The Company's focus is currently on developing two clinical candidates for the treatment of chronic hepatitis C infection. First, in collaboration with Gilead Sciences, Inc., Achillion is developing ACH-1095 (also known as GS-9525) a candidate from a unique class of compounds called NS4A antagonists which have been demonstrated to be synergistic or additive with other inhibitors under development for HCV infection. Second, Achillion is developing ACH-1625, a proprietary NS3 protease inhibitor. Each compound is expected to enter the clinic in the first half of 2009. Achillion is also developing ACH-702, its candidate for the treatment of serious, hospital-based bacterial infections. Both ACH-702 and the NS4A antagonists were discovered through Achillion's own proprietary internal drug discovery efforts.

Achillion is also finalizing its Phase II clinical program for elvucitabine, a novel nucleoside analog currently being evaluated for the treatment of patients with HIV. Achillion believes that elvucitabine addresses several of the limitations of currently marketed therapies and is an ideal candidate for partnerships around combination preparations and/or geographic commercialization alliances.

The company was founded in 1998 and is based in New Haven, Connecticut.